Short Sellers Grow More Selective on Major Biotechs
The May 13 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 212
Short Sellers Take Mixed Stance on Major Pharma
The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
PDL’s Next Acquisition Target Focus Is on Hypertension
PDL BioPharma Inc. (NASDAQ: PDLI) has now shown where its next revenue stream will be coming from. The company announced on Tuesday that it has committed to an equity investment in Noden Pharma DAC.…
Selecta Biosciences Files for IPO: Targeting Gout
Selecta Biosciences has filed its paperwork with the Securities and Exchange Commission to conduct an initial public offering (IPO) ahead. The company applied to list its common stock on The Nasdaq Global Market under…
Nant Health Announces Potential Pricing for IPO
Nant Health expects to price more than 6 million shares in the range of $12.50 to $15.50 for an initial public offering valued up to more than $115 million.
Are There More Insurance Giant Merger Risks?
Leerink issued a report telegraphing that health insurance mergers might be more at risk and that one is more likely to close.
Are Nanosphere Shareholders Getting Enough With This New Offer?
Nanosphere started the week off with a bang on Monday, following an update on an acquisition offer.
10 Speculative Biotech and Biohealth Stocks With Massive Analyst Upside Calls
Biotech is the one arena that still offers massive upside for investors — if they can pick the right companies that is. They could one day cure cancer, heart issues, diabetes and just about…
8 Stocks on the Move After ASCO Cancer Abstracts
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these abstracts.
Could This Be the Turning Point for Tonix Pharma?
Tonix Pharmaceuticals watched its shares take a handy jump early on Thursday, following positive results from its mid-stage PTSD study.
Cotiviti Announces Potential Pricing for IPO
Cotiviti expects to price more than 12 million shares in the range of $17 to $19 per share in an initial public offering valued up to more than $273 million.
Janney Remains Bullish on Editas Medicine
Editas Medicine Inc. (NASDAQ: EDIT) has become a rather interesting stock for many speculative biotech and biohealth investors. It has also been quite volatile. Its shares were trading higher on Monday after the release of…
Reata Pharma Fills in the Blanks for Its IPO
Reata Pharmaceuticals has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Investor Sentiment Is Horrible and Fund Outflows Are Huge: RBC Says Stay Positive
Three solid health care ideas featured by RBC are posting good numbers and expanding their product silos in an effort to continue to add new business.
Did Valeant Pharmaceuticals Capitulate Its Pricing?
Valeant Pharmaceuticals is trying to change its tune by announcing that it will offer an enhanced rebate program to all hospitals in the United States, in an effort to reduce the price of Nitropress…